Trial Profile
A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms DriveSaFe2
- Sponsors Janssen Research & Development
- 01 May 2022 Results published in the Journal of Psychopharmacology
- 27 Aug 2018 Status changed from recruiting to completed.
- 11 Mar 2018 Planned End Date changed from 30 Apr 2018 to 1 Oct 2018.